The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med.1993;329:977-986.
2.
Turner RC, Cull CA, Frighi V, Holman RR. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus. (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. JAMA. 1999;281:2005-2012.
3.
American Association of Clinical Endocrinologists. State of diabetes in America. Available at: http://www.aace.com/pub/StateofDiabetes/DiabetesAmericaReport.pdf. Accessed September 6, 2005.
4.
The Diabetes Control and Complications Trial Research Group. Weight gain associated with intensive therapy in the Diabetes Control and Complications Trial. Diabetes Care. 1988;11:567-573.
5.
Salle A, Guilloteau G, Ryan M, Bouhanick B, Ritz P. Effect of insulin treatment on the body composition of type 2 diabetic patients. Diabet Med.2004;21:1298-1303.
6.
Leese GP, Wang J, Broomhall J, et al. Frequency of severe hypoglycemia requiring emergency treatment in type 1 and type 2 diabetes: a population-based study of health service resource use. Diabetes Care. 2003;26:1176-1180.
7.
The Diabetes Control and Complications Trial Research Group. Hypoglycemia in the Diabetes Control and Complications Trial. Diabetes. 1997;46:271-286.
8.
Purnell JQ, Hokanson JE, Marcovina SM, Steffes MW, Cleary PA, Brunzell JD. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. JAMA. 1998;280:140-146.
9.
Cryer PE, Davis SN, Shamoon H.Hypoglycemia in diabetes. Diabetes Care. 2003;26:1902-1912.
10.
Kolotkin RL, Crosby RD, Williams GR. Assessing weightrelated quality of life in obese persons with type 2 diabetes. Diabetes Res Clin Pract.2003;61:125-132.
11.
Cox D, Gonder-Frederick L, McCall A, Kovatchev B, Clarke W.The effects of glucose fluctuation on cognitive function and QOL: the functional costs of hypoglycemia and hyperglycemia among adults with type 1 or type 2 diabetes. Int J Clin Pract Suppl.2002;129:20-26.
12.
Geelhoed-Duijvestijn PHLM, Peyrot M, Matthews DR, et al. Physician resistance to prescribing insulin: an international study [abstract]. Diabetologia. 2003;46(suppl 2):A274-A275. Abstract 793.
13.
Shah BR, Hux JE, Laupacis A, Zinman B, van Walraven C.Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?Diabetes Care. 2005;28:600-606.
14.
Funnell MM, Kruger DF. Type 2 diabetes: treat to target. Nurse Pract.2004;29:11-15, 19-23.
15.
Aventis Pharmaceuticals Inc.Lantus®: insulin glargine [rDNA origin] injection. Available at: http://www.aventis-us.com/PIs/lantus_TXT.html. Accessed August 2, 2005.
16.
Buse J, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care. 2004;27:2628-2635.
17.
DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (synthetic exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092-1100.
18.
Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control and weight in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083-1091.
19.
Riddle MC. Making the transition from oral to insulin therapy. Am J Med.2005;118(suppl 5S):S14-S20.
20.
Riddle MC, Rosenstock J, Gerich J, for the Insulin Glargine 4002 Study Investigators. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
21.
Raskin P, Allen E, Hollander P, et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care. 2005;28:260-265.
22.
Feinglos MN, Thacker CH, English J, Bethel MA, Lane JD. Modification of postprandial hyperglycemia with insulin lispro improves glucose control in patients with type 2 diabetes. Diabetes Care. 1997;20:1539-1542.
23.
Eldor R, Stern E, Milicevic Z, Raz I. Early use of insulin in type 2 diabetes. Diabetes Res Clin Pract.2005;68(suppl 1):S30-S35.
24.
Ryan EA, Imes S, Wallace C. Short-term intensive insulin therapy in newly diagnosed type 2 diabetes. Diabetes Care. 2004;27:1028-1032.
25.
Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med.2005;118(suppl 5S):S27-S34.
26.
Nichols GA, Gomez A. Weight changes associated with antihyperglycemic therapies for type 2 diabetes [abstract]. Diabetes. 2005;54(suppl 1):A4-A4. Abstract 13-OR.
27.
Kuritzky L, Nelson SE. Assessing the controversies of insulin therapy in patients with type 2 diabetes mellitus. J Fam Pract.2005;54(suppl):S3-S6.
28.
United Kingdom Prospective Diabetes Study Group. UK Prospective Diabetes Study 16. Overview of 6 years’ therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249-1258.
29.
United Kingdom Prospective Diabetes Study Group. United Kingdom Prospective Diabetes Study 24: a 6-year, randomized, controlled trial comparing sulfonylurea, insulin, and metformin therapy in patients with newly diagnosed type 2 diabetes that could not be controlled with diet therapy. Ann Intern Med.1998;128:165-175.
30.
Fineman MS, Shen LZ, Taylor K, Kim DD, Baron AD. Effectiveness of progressive dose-escalation of exenatide (exendin-4) on glycemic control in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev.2004;20:411-417.
31.
Blonde L, Han J, Mac S, Poon T, Taylor K, Kim D. Exenatide (exendin-4) reduced A1C and weight over 82 weeks in overweight patients with type 2 diabetes [abstract]. Diabetes Care. 2005;54(suppl 1):A118-A118. Abstract 477-P.
32.
Wilson M, Moore MP, Lunt H. Treatment satisfaction after commencement of insulin in type 2 diabetes. Diabetes Res Clin Pract.2004;66:263-267.
33.
Mollema ED, Snoek FJ, Ader HJ, Heine RJ, van der Ploeg HM. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general wellbeing. J Psychosom Res.2001;51:665-672.
34.
Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes Relat Metab Disord.2002;26(suppl 3):S18-S24.
35.
Siminerio L, Zgibor J, Solano FX Jr.Implementing the Chronic Care Model for improvements in diabetes practice and outcomes in primary care: the University of Pittsburgh Medical Center experience. Clin Diabetes. 2004;22:54-58.
36.
Barlow S, Johnson P. Patients use exenatide pen more successfully with educator-led training. Paper presented at: The American Association of Diabetes Educators 32nd Annual Meeting and Exhibition; August 13, 2005; Washington, DC.
37.
Ahern J, Kruger DF, Gatcomb PM, Petit WA Jr, Tamborlane WV. The Diabetes Control and Complications Trial (DCCT): the trial coordinator perspective. Report by the DCCT Research Group. Diabetes Educ.1989;15:236-241.
38.
Delahanty L, Simkins SW, Camelon K, for the DCCT Research Group. Expanded role of the dietitian in the Diabetes Control and Complications Trial: implications for clinical practice. J Am Diet Assoc.1993;93:758-764.
39.
Janes GR. Ambulatory medical care for diabetes. In: Group NDD, ed. Diabetes in America. Vol. 95-1468. Bethesda, Md: National Institutes of Health; 1995:541-552.
40.
Siminerio L. Implementing diabetes self-management education programs: breaking through the barriers in primary care. Endocr Practice. 2006;12[Suppl 1]:124-130.
